Diagnosis & Disease Information

The percentage of patients with stage I disease increased from 23.5% in 2010 to 29.1% in 2017.

The overall response rate was 33%, with 1% of patients having complete responses and 32% having partial responses.

TACTI-002, enrolled 114 patients with untreated locally advanced or metastatic non-small cell lung cancer, unselected for PD-L1 expression.

The researchers noted that responses were deep, with 75% of responders achieving a greater than 50% tumor reduction.

Results showed a median overall survival of 25.0 months for chemo-immunotherapy vs 20.9 months for immunotherapy alone.